

February 4, 2026

To Shareholders,

Company Name: Renascience Inc.
Representative: Toshio Miyata, Chairman and CEO
(Code: 4889 TSE Growth)
For inquiries, please contact Administration Dept.

Safety Confirmation Test for the PAI-1 Inhibitor RS5614 in Dogs and Cats

Our PAI-1 inhibitor RS5614 is being developed as a prescription drug for human cancer and lung diseases (chronic myeloid leukemia, malignant melanoma, angiosarcoma, non-small cell lung cancer, and systemic sclerosis, etc). Meanwhile, as evidenced by the development of our PAI-1 inhibitor RS5441¹⁾ as a topical treatment for male pattern baldness or age-related alopecia, our company is also considering expanding our business into the anti-aging and longevity fields, which are important themes for over-the-counter drugs²⁾ and veterinary medicines, which are experiencing rapid growth due to the hyper-aging population.

RS5614's anti-aging and longevity effects and pharmacological properties are expected to be useful not only in human medicine, but also in veterinary medicine, including companion animals³⁾, primarily dogs and cats, and therefore we have begun research into veterinary medicine targeting dogs and cats. We are pleased to announce that safety confirmation studies of RS5614 in dogs and cats have been conducted and the results have been obtained.

[Dog Safety Examination]

Contractor: Shokukanken Inc. (<https://www.shokukanken.com/>)

Dog breed: Beagle

Number of dogs: n=3

Dose: RS5614 15mg/kg (more than 10 times the expected effective dose)

Administration period: 28 days

Administration route: oral

Examinations: general symptom observation, food intake, body weight measurement, hematology⁴⁾ and blood biochemistry⁵⁾

Results: No abnormalities were found in all examinations.

*The minimum effective dose of anti-thrombotic effects in rats, monkeys, or humans was 1 mg/kg, 0.1 mg/kg, and 1.5-2.0 mg/kg, respectively.

[Cat Safety Examination]

Contractor: Shokukanken Inc.

Cat breed: Mixed breed

Number of cats: n=3

Dose: RS5614 15mg/kg (more than 10 times the expected effective dose)

Administration period: 28 days

Administration route: oral

Examinations: general symptom observation, food intake, body weight measurement, hematology and blood biochemistry

Results: Food intake decreased transiently and final body weight decreased by approximately 4%, but no significant adverse events were observed in general symptom observation, hematology, and blood biochemistry.

We plan to conduct clinical trials to evaluate the efficacy of this product in dogs (arthritis, melanoma, and other skin cancers) and cats (chronic kidney disease).

We expect the impact of this matter on our financial results for the fiscal year ending March 31, 2026, to be minor. However, we will promptly disclose any future disclosures that require disclosure.

¹⁾ RS5441

We license RS5441, the active ingredient in ET-02, a topical medication for male pattern baldness and age-related alopecia, that Eirion develops. While RS5441 was developed by our company, clinical trials for male pattern baldness or age-related alopecia are conducted by Eirion.

²⁾ OTC (over-the-counter) Drugs

These are not "prescription drugs" that require a doctor's prescription, but are drugs that can be purchased without a prescription at pharmacies and drugstores.

³⁾ Companion Animals

This refers to animals, primarily dogs and cats, kept at home and living with humans. More than just pets, they are often treated as family members, and in recent years, with the aging population, demand for them in the medical and healthcare fields has expanded significantly.

⁴⁾ Hematology Testing

This test measures the number and morphology of cellular components in the blood (red blood cells, white blood cells, and platelets).

⁵⁾ Blood Chemistry Testing

This test chemically measures enzymes, sugars, proteins, lipids, electrolytes, and other components contained in the liquid component of blood (serum).